Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0TH Open: Companion Journal to Thrombosis and Haemostasis

Rivaroxaban Counteracts the Adverse Effects of Warfarin on Plaque Vulnerability and Vessel Wall Remodelling

4 affiliations
  1. 1Department of Biochemistry Cardiovascular Research Institute Maastricht, Maastricht University Maastricht Limburg The Netherlands
  2. 2Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz Mainz Rhineland-Palatinate Germany
  3. 3Department of Nephrology University of Montpellier Montpellier Occitanie France
  4. 4Thrombosis Expertise Center, Heart and Vascular Center, Maastricht University Medical Centre+ Maastricht Limburg The Netherlands

Abstract

Atherosclerosis is a major cause of cardiovascular diseases (CVDs) globally, characterized by vascular calcification (VC), increasing the risk of myocardial infarction and stroke. Oral anticoagulants are widely prescribed to prevent recurrent thrombotic events. However, increasing concern surrounds warfarin, whose unfavorable pharmacokinetic profile and interference with vitamin K-dependent pathways have been implicated in VC. Rivaroxaban represents an alternative anticoagulant, yet its ability to mitigate warfarin-induced vascular injury remains insufficiently defined. This study investigated whether switching from warfarin to rivaroxaban benefits plaque progression and might hold progression of calcification. Apolipoprotein E-deficient (

Apoe −/− ) mice were fed a Western-type diet (WTD) for 18 weeks, supplemented without (control) or with either warfarin or rivaroxaban. An additional group received warfarin for 6 weeks, after which they switched to rivaroxaban for 12 weeks. Plaque size was comparable in both the continuous rivaroxaban group and the switching group and was decreased compared with 18 weeks in both the warfarin and control groups. Notably, VC was decreased in both rivaroxaban groups, with a more significant decrease observed in the switching group compared with continuous warfarin treatment. The switching group showed better vascular integrity with lower vascular stiffness and fewer elastic fiber breaks. Additionally, the switching group showed features of a more stable plaque phenotype with increased α-smooth muscle actin (αSMA)-positive vascular smooth muscle cells and a higher collagen content. Interestingly, all three anticoagulation therapies showed decreased expression of protease-activated receptor 2 (PAR2) together with a decrease in oxidative stress in the plaques. However, only rivaroxaban treatments showed reduced matrix metalloproteinase 9 (MMP-9) expression in plaques compared with both control and warfarin groups. Our results suggest that rivaroxaban ameliorates the adverse effects of warfarin, offering significant benefits on atherosclerotic burden and plaque stability. Transitioning from warfarin to rivaroxaban has the potential to reshape clinical practice by offering anticoagulation and reducing the practical limitations associated with vitamin K antagonists, particularly in patients with coexisting CVDs.

Related

  1. A bicentric pilot study of apixaban and rivaroxaban quantification using a novel Point-Of-Care system in the emergency department
    Cindy Tissier, Tiffany Madranges, Nicolas Peschanski +4
    Research and Practice in Thrombosis and HaemostasisPeer-reviewedCC BY-NC-NDGeneral biologyHAL
  2. Forced expression of UCP1 counteracts the compromised activity of NK cells in the tumor microenvironment
    Min Gu, Weiwei Chen, Chunmiao Hu +5
    Communications BiologyPeer-reviewedCC BY-NC-ND 4.0Full textImmunologyCrossref
  3. Dynorphin counteracts excitatory co-transmission in a lateral hypothalamus–locus coeruleus circuit underlying stress-induced anxiety
    Yin-Yin Yang, Huanyao Tang, Ke-Xue Li +5
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textNeuroscienceCrossref
  4. Restoration of (nor)adrenergic-like Ca2+ signalling counteracts age-related motor decline
    A. Horvat, U. Cerne, A.-K. Dahse +7
    bioRxivPreprintCC BYFull textNeurosciencebioRxiv
  5. Acute ischemic stroke associated with Moringa oleifera and protein powder consumption in a patient on warfarin: A coagulation paradox and clinical blind spot.
    Yuta Kobayashi, Akinori Onuki, Kazuomi Horiuchi +7
    Surgical neurology internationalPeer-reviewedCC BY-NC-SAFull textPlant biologyEurope PMCPMC
BibTeX
@article{habibi2026rivaroxaban,
  title = {{Rivaroxaban Counteracts the Adverse Effects of Warfarin on Plaque Vulnerability and Vessel Wall Remodelling}},
  author = {Anxhela Habibi and Vanessa Broker and Juliana H. Boukhaled and Dani Veldhuis and Jenny Surholt and Peter Leenders and Cecile Maassen and Magdolna Nagy and Henri M.H. Spronk and Wolfram Ruf and Leon J. Schurgers and Armand M.G. Jaminon},
  journal = {TH Open: Companion Journal to Thrombosis and Haemostasis},
  year = {2026},
  month = oct,
  doi = {10.1055/a-2979-1901},
  url = {https://doi.org/10.1055/a-2979-1901},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Rivaroxaban Counteracts the Adverse Effects of Warfarin on Plaque Vulnerability and Vessel Wall Remodelling
AU  - Anxhela Habibi
AU  - Vanessa Broker
AU  - Juliana H. Boukhaled
AU  - Dani Veldhuis
AU  - Jenny Surholt
AU  - Peter Leenders
AU  - Cecile Maassen
AU  - Magdolna Nagy
AU  - Henri M.H. Spronk
AU  - Wolfram Ruf
AU  - Leon J. Schurgers
AU  - Armand M.G. Jaminon
PY  - 2026
DA  - 2026/10/21
JO  - TH Open: Companion Journal to Thrombosis and Haemostasis
DO  - 10.1055/a-2979-1901
UR  - https://doi.org/10.1055/a-2979-1901
AB  - Atherosclerosis is a major cause of cardiovascular diseases (CVDs) globally, characterized by vascular calcification (VC), increasing the risk of myocardial infarction and stroke. Oral anticoagulants are widely prescribed to prevent recurrent thrombotic events. However, increasing concern surrounds warfarin, whose unfavorable pharmacokinetic profile and interference with vitamin K-dependent pathways have been implicated in VC. Rivaroxaban represents an alternative anticoagulant, yet its ability to mitigate warfarin-induced vascular injury remains insufficiently defined. This study investigated whether switching from warfarin to rivaroxaban benefits plaque progression and might hold progression of calcification. Apolipoprotein E-deficient (  Apoe −/− ) mice were fed a Western-type diet (WTD) for 18 weeks, supplemented without (control) or with either warfarin or rivaroxaban. An additional group received warfarin for 6 weeks, after which they switched to rivaroxaban for 12 weeks. Plaque size was comparable in both the continuous rivaroxaban group and the switching group and was decreased compared with 18 weeks in both the warfarin and control groups. Notably, VC was decreased in both rivaroxaban groups, with a more significant decrease observed in the switching group compared with continuous warfarin treatment. The switching group showed better vascular integrity with lower vascular stiffness and fewer elastic fiber breaks. Additionally, the switching group showed features of a more stable plaque phenotype with increased α-smooth muscle actin (αSMA)-positive vascular smooth muscle cells and a higher collagen content. Interestingly, all three anticoagulation therapies showed decreased expression of protease-activated receptor 2 (PAR2) together with a decrease in oxidative stress in the plaques. However, only rivaroxaban treatments showed reduced matrix metalloproteinase 9 (MMP-9) expression in plaques compared with both control and warfarin groups. Our results suggest that rivaroxaban ameliorates the adverse effects of warfarin, offering significant benefits on atherosclerotic burden and plaque stability. Transitioning from warfarin to rivaroxaban has the potential to reshape clinical practice by offering anticoagulation and reducing the practical limitations associated with vitamin K antagonists, particularly in patients with coexisting CVDs.
SN  - 2567-3459
SN  - 2512-9465
ER  -